Some problems in the bioassay of haematological drugs.
The principles of biological standardization are well understood and generally accepted. However, discrepancies in potency estimates due to inter-method and inter-laboratory variations in assay hinder general agreement on potency values for certain biological drugs used in treating disorders of haemostatis. While attempts are made to minimize these differences, the magnitude of existing inter-laboratory discrepancies should be acknowledged.
D000990:Antithrombin III / Q000032:analysis; D001681:Biological Assay; D005164:Factor IX / Q000032:analysis; D005169:Factor VIII / Q000032:analysis; D006490:Hemostatics / Q000032:analysis*; D006493:Heparin / Q000032:analysis; D006801:Humans; D010958:Plasminogen / Q000032:analysis; D011786:Quality Control; D012015:Reference Standards; D006113:United Kingdom; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis
D006490:Hemostatics; D000990:Antithrombin III; D005169:Factor VIII; D005164:Factor IX; D010958:Plasminogen; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator